Aethlon Medical is a revenue-stage organization that creates therapeutic devices to address unmet needs in cancer, infectious disease, and sepsis. The Company’s lead product, the Aethlon ADAPT™ system represents the intersection of modern medical device technology and affinity drug mechanisms. This technology platform originates a new class of therapies that permit the selective removal of disease enhancing particles from the entire circulatory system without drug toxicity. The Aethlon ADAPT™ system is marketed to government health and military agencies with programs to address life-threatening disease conditions, as well as to biotechnology and pharmaceutical organizations that wish to pursue a medical device regulatory and commercialization pathway for their drug agents. Beyond revenue generation, the ADAPT™ system allows Aethlon to create an expansive yet cohesive pipeline of proprietary therapeutics. At present, the Aethlon ADAPT™ pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, HER2osome™ to target HER2+ breast cancer, and a medical device to prevent sepsis in combat-injured soldiers that is being developed under a $6.8 million contract award from the Defense Advanced Research Projects Agency (DARPA).